Navigation Links
Reportlinker Adds Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017

NEW YORK, March 9, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017

SummaryGlobalData, the industry analysis specialist, has released its new report, "Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Diabetic Retinopathy (DR) therapeutics market. The report identifies the key trends shaping and driving the global DR therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global DR therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global Diabetic Retinopathy therapeutics market was valued at $169m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 35.5% over the next seven years and reach $1.41 billion by 2017. This high growth is largely due to the growth in the diabetes population and a strong pipeline which includes first-in-class drugs with disease-modifying properties as well as better safety and efficacy profile. Approval of LUCENTIS (ranibizumab), Macugen (pegaptanib), Arxxant (ruboxistaurin) and Nevanac (nepafenac) is expected to drive the future market.

ScopeThe report provides information on the key drivers and challenges of the DR therapeutics market. Its Scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) DR therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major protein kinase inhibitors, VEGF inhibitors, Prostaglandin H synthase (cyclooxygenase) inhibitors, Angiopoietin/Tie-2 antagonist, Immunomodulators.

- Analysis of the current and future competition in the seven key countries DR therapeutics market. Key market players covered are Eli-Lilly, Roche, Pfizer Inc., Alcon/Novarits and Vitreoretinal Technologies.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the DR therapeutics market.

- Analysis of key recent licensing and partnership agreements in DR therapeutics market.

Reasons to buyThe report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global DR therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global DR therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global DR therapeutics market landscape? – Identify, understand and capitalize

To order this report:: Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds World Market for Molecular Diagnostics: Potential and Reality, Whats Hot and Whats Not , The
2. Reportlinker Adds Three Alternative Scenarios of the Future In Vitro Diagnostics Market through 2018
3. Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan; Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
4. Reportlinker Adds The 2011 Top Ten Worlds Leading Life Science Intermediates Companies
5. Reportlinker Adds Biomarkers - Technologies, Markets and Companies
6. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
7. Reportlinker Adds RNAi - Technologies, Markets and Companies
8. Reportlinker Adds Future Outlook for Common IT Platforms - Radiology and Cardiology
9. Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers
10. Reportlinker Adds Propylene Oxide: 2010 World Market Outlook and Forecast
11. Reportlinker Adds Global Marine Biotechnology Industry
Post Your Comments:
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... NEWPORT BEACH, Calif. , June 23, 2016 /PRNewswire/ ... offering new biological discoveries to the medical community, has ... and co-founder Matthew Nunez . "We ... provide us with the capital we need to meet ... funding will essentially provide us the runway to complete ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
Breaking Biology Technology:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: ... to provide their customers enhanced security to access ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):